Nevirapine
- Generic Name
- Nevirapine
- Brand Names
- Viramune
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N4O
- CAS Number
- 129618-40-2
- Unique Ingredient Identifier
- 99DK7FVK1H
- Background
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 123
- Registration Number
- NCT00273975
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Tygerberg, South Africa
🇿🇦Groote Schuur Hospital, Cape Town, South Africa
Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT00273988
- Locations
- 🇮🇪
Department of Genito Urinary Medicine, St James' Hospital, Dublin, Ireland
Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
- Conditions
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 730
- Registration Number
- NCT00270296
- Locations
- 🇧🇼
Athlone Hosp., BHP Study Clinic, Lobatse Shapiro CRS, Lobatse, Botswana
🇧🇼Princess Marina Hosp., BHP Study Clinic, Gaborone Shapiro CRS, Gaborone, Botswana
🇧🇼Deborah Reteif Hosp., BHP Study Clinic, Mochudi Shapiro CRS, Mochudi, Botswana
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2021-11-09
- Target Recruit Count
- 75
- Registration Number
- NCT00260078
- Locations
- 🇺🇸
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States
🇺🇸Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States
Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- CIPRA SA
- Target Recruit Count
- 812
- Registration Number
- NCT00255840
When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
- Conditions
- Interventions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2013-12-04
- Target Recruit Count
- 300
- Registration Number
- NCT00234091
- Locations
- 🇰🇭
National Pediatric Hosp., Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇰🇭Social Health Clinic, Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇹🇭Prapokklao Hosp. CIPRA CRS, Chantaburi, Thailand
Prevention of Milk-Borne Transmission of HIV-1C in Botswana
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Harvard School of Public Health (HSPH)
- Target Recruit Count
- 1200
- Registration Number
- NCT00197587
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- MEDEX
- Target Recruit Count
- 250
- Registration Number
- NCT00199979
- Locations
- 🇫🇷
Cisih, Clinique Medical A, Hopitaux Universitaires, Strasbourg, Alsace, France
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
ATV/Ritonavir Nevirapine Interaction (USPAC)
- Conditions
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00162149
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.